SCHEMBL19274232

SCHEMBL19274232

CCCC=C(C)Nc1nc(N)ncc1OCc1cn2ccccc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ TLR7 Q9NYK1 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ TDP1 Q9NUW8 3/20 0.39
▸ TSHR P16473 1/20 0.38
▸ HRH4 Q9H3N8 1/20 0.38
▸ PDE10A Q9Y233 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ MAPK10 P53779 1/20 0.36
▸ TP53 P04637 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ SIRT5 Q9NXA8 1/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ CYP1A2 P05177 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19274250 0.93 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1LMNAKDM4ENPC1
SCHEMBL13195702 0.81 TLR7 (0.60) SMN1; SMN2ALDH1A1LMNAKDM4ENPC1
SCHEMBL15470285 0.79 TLR7 (0.44) SMN1; SMN2ALDH1A1LMNAKDM4ENPC1
SCHEMBL15470282 0.79 TLR7 (0.44) SMN1; SMN2ALDH1A1LMNAKDM4ENPC1
SCHEMBL20219666 0.79 TLR7 (0.44) SMN1; SMN2ALDH1A1LMNAKDM4ENPC1
SCHEMBL15470199 0.79 TLR8 (0.44) SMN1; SMN2ALDH1A1LMNAKDM4ENPC1
SCHEMBL15470178 0.78 KCNH2 (0.46) SMN1; SMN2ALDH1A1LMNAKDM4ENPC1
SCHEMBL15470210 0.78 TLR8 (0.47) SMN1; SMN2ALDH1A1LMNAKDM4ENPC1
SCHEMBL15470181 0.77 KCNH2 (0.48) SMN1; SMN2KDM4ENPC1RAB9ATLR7
SCHEMBL20219598 0.77 NPC1 (0.52) SMN1; SMN2ALDH1A1LMNAKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11541050-B2 Pyrimidine derivatives for the treatment of viral infections JANSSEN SCIENCES IRELAND UC (IE) 2023-01-03 — — US disclosed
US-20210023082-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UC (IE) 2021-01-28 — — US disclosed
US-10780089-B2 Pyrimidine derivatives for the treatment of viral infections JANSSEN SCIENCES IRELAND UC (IE) 2020-09-22 — — US disclosed
US-20200061059-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UC (IE) 2020-02-27 — — US disclosed
US-10420767-B2 Pyrimidine derivatives for the treatment of viral infections JANSSEN SCIENCES IRELAND UC (IE) 2019-09-24 — — US disclosed
US-10272085-B2 Pyrimidine derivatives for the treatment of viral infections JANSSEN SCIENCES IRELAND UC (IE) 2019-04-30 — — US disclosed
US-20180207155-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UC (IE) 2018-07-26 — — US disclosed
US-20170239245-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UC (IE) 2017-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10780089-B2 Pyrimidine derivatives for the treatment of viral infections TYMP, UMPS, HPRT1 SMN1; SMN2 3359/4885ALDH1A1 1826/4885LMNA 3150/4885
US-20200061059-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS TYMP, UMPS, HPRT1 SMN1; SMN2 3359/4885ALDH1A1 1826/4885LMNA 3150/4885
US-10420767-B2 Pyrimidine derivatives for the treatment of viral infections TYMP, UMPS, HPRT1 SMN1; SMN2 3359/4885ALDH1A1 1826/4885LMNA 3150/4885
US-10272085-B2 Pyrimidine derivatives for the treatment of viral infections TYMP, UMPS, HPRT1 SMN1; SMN2 3359/4885ALDH1A1 1826/4885LMNA 3150/4885
US-11541050-B2 Pyrimidine derivatives for the treatment of viral infections TYMP, UMPS, HPRT1 SMN1; SMN2 3359/4885ALDH1A1 1826/4885LMNA 3150/4885
US-20210023082-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS TYMP, UMPS, HPRT1 SMN1; SMN2 3359/4885ALDH1A1 1826/4885LMNA 3150/4885
US-20180207155-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS TYMP, UMPS, HPRT1 SMN1; SMN2 3359/4885ALDH1A1 1826/4885LMNA 3150/4885
US-20170239245-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS TYMP, UMPS, HPRT1 SMN1; SMN2 3359/4885ALDH1A1 1826/4885LMNA 3150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback